Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Novartis: Dismal performance continues - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 31, 2003

    Novartis: Dismal performance continues

    MNC pharma major, Novartis, announced dismal 2QFY04 results yesterday. The company has reported a 5% drop in topline and a 17% decline in bottomline. For 1HFY04, while the net sales have dropped marginally, pressure on margins has resulted in a 9% drop in net profits. In this context, let us briefly evaluate the company’s performance during the period under review.

    Results at a glance...
    (Rs m) 2QFY03 2QFY04 Change 1HFY03 1HFY04 Change
    Net Sales 1,306 1,245 -4.6% 2,581 2,573 -0.3%
    Other Income 231 218 -5.5% 271 299 10.4%
    Expenditure 1,074 1,098 2.3% 2,106 2,242 6.5%
    Operating Profit (EBDIT) 232 147 -36.7% 476 331 -30.5%
    Operating Profit Margin (%) 17.8% 11.8%   18.4% 12.8%  
    Interest 2 2 -14.3% 4 4 -9.3%
    Depreciation 54 39 -28.1% 75 77 2.5%
    Profit before Tax 407 325 -20.3% 668 550 -17.7%
    Tax 89 60 -32.4% 183 109 -40.7%
    Profit after Tax/(Loss) 318 265 -16.9% 485 441 -9.1%
    Net profit margin (%) 24.4% 21.2%   18.8% 17.1%  
    No. of Shares (m) 31.96 31.96   31.96 31.96  
    Earnings per share (Rs)* 39.8 33.1   30.3 27.6  
    P/E (x)   9.0     10.8  

    Intense competition in its generics business has resulted in Novartis registering a decline in topline during 2QFY04 as compared to the corresponding previous quarter. Poor performance of the company’s ‘Rifampicin’ business (a key ingredient for the anti-TB range) has put further pressure on the topline. ‘Rifampicin’, has come under intense pricing pressure due to the downward revision of prices by National Pharmaceutical Pricing Authority (NPPA). In view of the continued poor performance of this business, Novartis is now evaluating options to reduce its exposure in the same.

    Expenditure as a % of sales
    (Rs m) 2QFY03 2QFY04 1HFY03 1HFY04
    Purchase of materials & finished goods 51.4% 51.2% 50.8% 52.8%
    Staff cost 8.3% 8.7% 8.6% 9.0%
    Others 22.5% 28.3% 22.2% 25.4%

    On the operations front, rise in other expenditure and staff cost as a percentage of net sales has resulted in Novartis recording a 600 basis point drop in operating profit margins. The other expenditure has increased due to higher promotional expenses. However, the increased investments in promotional expenses have not translated into higher revenues for the company. Despite a reduction in interest cost and lower depreciation provision, pressure on operating profit margin and lower other income has resulted in Novartis recording a 17% drop in bottomline. The other income has declined due to lower profit on sale of land as compared to corresponding previous period.

    At Rs 298, Novartis is trading at a P/E of 11x its annualised 1HFY04 earnings. Novartis is in a restructuring phase and is in the process of selling off its surplus property and reducing its workforce. Although the above initiatives augur well for the company going forward, in the near term, the company is facing intense pricing pressure. Moreover, with the implementation of the new DPCO, a major portion of its product portfolio is expected to come under DPCO cover. In view of the above, we expect the company to continue to witness low growth in the medium term.



    Equitymaster requests your view! Post a comment on "Novartis: Dismal performance continues". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 21, 2017 (Close)


    • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts